Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UV 2

X
Drug Profile

UV 2

Alternative Names: TENDU; UV-2; UV2 synthetic peptide vaccine

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ultimovacs AS
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 04 Apr 2024 Phase I clinical development of UV 2 is still going on in Norway (NCT04701021)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Prostate-cancer(In the elderly, Second-line therapy or greater, In adults) in Norway (SC, Injection)
  • 21 Mar 2024 Ultimovacs has patent pending for composition of matter of TENDU conjugates and vaccine compositions and use thereof for the prevention or treatment of cancer, T-cell epitopes of the conjugates and the encoding nucleic acid molecules in Europe, Japan, Australia and Canada
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top